Blinatumomab is primarily used for treating certain types of blood cancers, particularly acute lymphoblastic leukemia (ALL). It is especially beneficial for patients who have relapsed or refractory B-cell precursor ALL. Although its primary indication is for ALL, ongoing research explores its efficacy in other cancers expressing the CD19 protein.
